Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

1.0K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating the relationship between psoriatic arthritis, multiple long-term conditions, treatment burden and adverse clinical outcomes: A systematic review protocol.

Journal of multimorbidity and comorbidity·2026
Same author

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.

Lancet (London, England)·2026
Same author

Mixed (reusable/single-use) catheter management versus single-use catheter management for intermittent catheter users (MultICath): A non-inferiority randomised controlled trial.

International journal of nursing studies·2026
Same author

Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System.

Journal of the American College of Cardiology·2026
Same author

Long-term Safety and Performance of an Implantable IVC Sensor for Congestion-Guided Management in Heart Failure: 12-Month Results from the FUTURE-HF Trial Portfolio.

European journal of heart failure·2026
Same author

SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure.

European journal of heart failure·2026

Related Experiment Video

Updated: May 2, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K

ICDs in end-stage heart failure.

Stephen J Pettit1, Susan Browne, Karen J Hogg

  • 1Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, UK.

BMJ Supportive & Palliative Care
|March 22, 2014
PubMed
Summary
This summary is machine-generated.

Implantable cardioverter defibrillators (ICDs) may offer less benefit in advanced heart failure. Discussing ICD deactivation is crucial but often overlooked, highlighting a gap between best practice and patient care.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

2.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K

Related Experiment Videos

Last Updated: May 2, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

2.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K

Area of Science:

  • Cardiology
  • Medical Ethics
  • Palliative Care

Background:

  • Implantable cardioverter defibrillators (ICDs) improve survival in select chronic heart failure patients.
  • Prognostic benefits of ICDs may diminish in end-stage heart failure.
  • The frequency of futile ICD shocks before death is not well-established.

Purpose of the Study:

  • To explore the uncertainty surrounding the futility of ICD therapy in end-stage heart failure.
  • To investigate patient and carer perspectives on ICD deactivation.
  • To identify barriers to discussing ICD deactivation in clinical practice.

Main Methods:

  • Literature review on ICD use in advanced heart failure.
  • Analysis of clinical guidelines and expert consensus.
  • Qualitative research exploring patient and healthcare professional views (implied).

Main Results:

  • The prognostic benefit of ICDs likely decreases as heart failure progresses.
  • Decisions regarding ICD futility are best made by individual patients with professional support.
  • Routine discussion of ICD deactivation is recommended but infrequently practiced.

Conclusions:

  • Patient and carer opinions on ICD deactivation may differ from healthcare professionals' expectations.
  • Further research is needed on patient/carer views and interventions to improve deactivation discussions.
  • Bridging the gap between recommended practice and actual clinical implementation is essential.